Hypoxia-inducible Factors and Cancer

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2007 May 26

PMID 17525038

Citations 20

Authors

M J Calzada

L del Peso

Affiliations

Soon will be listed here.

Abstract

Decreased oxygen availability is a common feature during embryonic development as well of malignant tumours. Hypoxia regulates many transcription factors, and one of the most studied is the hypoxia-inducible factor (HIF). As a consequence of HIF stabilisation, the cell constitutively upregulates the hypoxic programme resulting in the expression of genes responsible for global changes in cell proliferation, angiogenesis, metastasis, invasion, de-differentiation and energy metabolism. Of the three known alpha subunits of HIF transcription factors, HIF-1alpha and HIF-2alpha have been the most studied. Their differential expression and function have been widely discussed, however no clear picture has been drawn on how these two transcription factors differently regulate common and unique target genes. Their role as oncogenes has also been suggested in several studies. In this review we provide an overview of the current knowledge on some of the most important aspects of HIFalpha regulation, its role in tumour angiogenesis and energetic metabolism. We also give an overview of how the modulation of HIF regulating pathways is a potential therapeutic target that may have benefits in the treatment of cancer.

Citing Articles

Correlation between imaging and tissue biomarkers of hypoxia in squamous cell cancer of the head and neck.

Kunder S, Chatterjee A, Manna S, Mahimkar M, Patil A, Rangarajan V World J Nucl Med. 2021; 20(3):228-236.

PMID: 34703390 PMC: 8488888. DOI: 10.4103/wjnm.WJNM_91_20.

Effect of an ionic antineoplastic agent Cytoreg on blood chemistry in a Wistar rat model.

Villasana K, Quintero W, Montero Y, Pino C, Uzcategui O, Torres G Med Gas Res. 2021; 12(1):18-23.

PMID: 34472498 PMC: 8447950. DOI: 10.4103/2045-9912.324592.

Unlocking mammalian regeneration through hypoxia inducible factor one alpha signaling.

DeFrates K, Franco D, Heber-Katz E, Messersmith P Biomaterials. 2021; 269:120646.

PMID: 33493769 PMC: 8279430. DOI: 10.1016/j.biomaterials.2020.120646.

Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy-results from a prospective trial.

Nicolay N, Wiedenmann N, Mix M, Weber W, Werner M, Grosu A Eur J Nucl Med Mol Imaging. 2019; 47(5):1046-1055.

PMID: 31811344 DOI: 10.1007/s00259-019-04598-9.

The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies.

Araos J, Sleeman J, Garvalov B Clin Exp Metastasis. 2018; 35(7):563-599.

PMID: 30171389 DOI: 10.1007/s10585-018-9930-x.

References

Kim M, Yan Y, Lee K, Sgagias M, Cowan K . Ectopic expression of von Hippel-Lindau tumor suppressor induces apoptosis in 786-O renal cell carcinoma cells and regresses tumor growth of 786-O cells in nude mouse. Biochem Biophys Res Commun. 2004; 320(3):945-50. DOI: 10.1016/j.bbrc.2004.06.042. View

Mylonis I, Chachami G, Samiotaki M, Panayotou G, Paraskeva E, Kalousi A . Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem. 2006; 281(44):33095-106. DOI: 10.1074/jbc.M605058200. View

Berra E, Richard D, Gothie E, Pouyssegur J . HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1alpha degradation. FEBS Lett. 2001; 491(1-2):85-90. DOI: 10.1016/s0014-5793(01)02159-7. View

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

Phelan M, Forman L, Perrine S, Faller D . Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells. J Lab Clin Med. 1998; 132(6):519-29. DOI: 10.1016/s0022-2143(98)90131-7. View

Takeda N, Maemura K, Imai Y, Harada T, Kawanami D, Nojiri T . Endothelial PAS domain protein 1 gene promotes angiogenesis through the transactivation of both vascular endothelial growth factor and its receptor, Flt-1. Circ Res. 2004; 95(2):146-53. DOI: 10.1161/01.RES.0000134920.10128.b4. View

Cockman M, Lancaster D, Stolze I, Hewitson K, McDonough M, Coleman M . Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc Natl Acad Sci U S A. 2006; 103(40):14767-72. PMC: 1578504. DOI: 10.1073/pnas.0606877103. View

Cummins E, Berra E, Comerford K, Ginouves A, Fitzgerald K, Seeballuck F . Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A. 2006; 103(48):18154-9. PMC: 1643842. DOI: 10.1073/pnas.0602235103. View

10.

Brugarolas J, Vazquez F, Reddy A, Sellers W, Kaelin Jr W . TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 2003; 4(2):147-58. DOI: 10.1016/s1535-6108(03)00187-9. View

11.

Jaakkola P, Mole D, Tian Y, Wilson M, Gielbert J, Gaskell S . Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292(5516):468-72. DOI: 10.1126/science.1059796. View

12.

Esteban M, Tran M, Harten S, Hill P, Castellanos M, Chandra A . Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res. 2006; 66(7):3567-75. DOI: 10.1158/0008-5472.CAN-05-2670. View

13.

Kaelin Jr W . Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002; 2(9):673-82. DOI: 10.1038/nrc885. View

14.

Schmid T, Zhou J, Kohl R, Brune B . p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1). Biochem J. 2004; 380(Pt 1):289-95. PMC: 1224165. DOI: 10.1042/BJ20031299. View

15.

Bindra R, Vasselli J, Stearman R, Linehan W, Klausner R . VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 2002; 62(11):3014-9. View

16.

Avila P, Alvarez-Tejado M, Gutierrez M, Garcia-Pardo A, Sanchez-Madrid F, Landazuri M . Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions. Cancer Res. 2002; 62(10):2929-36. View

17.

Maynard M, Qi H, Chung J, Lee E, Kondo Y, Hara S . Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem. 2003; 278(13):11032-40. DOI: 10.1074/jbc.M208681200. View

18.

Covello K, Simon M, Keith B . Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res. 2005; 65(6):2277-86. DOI: 10.1158/0008-5472.CAN-04-3246. View

19.

Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L . Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell. 2005; 8(2):131-41. DOI: 10.1016/j.ccr.2005.07.003. View

20.

Nagasawa H, Uto Y, Kirk K, Hori H . Design of hypoxia-targeting drugs as new cancer chemotherapeutics. Biol Pharm Bull. 2006; 29(12):2335-42. DOI: 10.1248/bpb.29.2335. View